Highest-materiality recent filing
PepGen stockholders elect three Class I directors, ratify KPMG as auditor
Howard Mayer, M.D. elected with 36.1M votes for, 8.5M withheld; Joshua Resnick and Lisa Wyman also elected.
PepGen updates corporate presentation for IDMC meeting; no specific news disclosed
PepGen to present at 15th International Myotonic Dystrophy Consortium (May 26-30, 2026).
PepGen Q1 net loss $17.8M; cash $132.3M; 10 mg/kg DM1 cohort fully enrolled
Net loss of $17.8M ($0.26 per share) vs $30.2M loss in Q1 2025; R&D spend down to $13.0M from $25.4M.
5 mg/kg cohort (n=8): mean splicing correction 7.3% overall, 22.9% excluding outlier; placebo 6.8%.
PepGen reports FY2025 net loss $89.7M; FDA partial hold on FREEDOM2 trial
FDA placed partial clinical hold on FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1; questions relate to preclinical studies, not clinical data.
Filed under Regulation FD to update corporate presentation (Exhibit 99.1).
PepGen appoints Joseph Vittiglio as Chief Business and Legal Officer
Joseph Vittiglio named Chief Business and Legal Officer, effective December 8, 2025.
PepGen reports Q3 net loss of $18.0M; 53.7% splicing correction in DM1 Phase 1
FREEDOM-DM1 15 mg/kg showed mean splicing correction of 53.7%, highest reported in DM1 patients.
PepGen reprices underwater stock options to $4.53 for key employees including CEO, CFO, EVP
Repriced 3,557,903 shares held by employees and named executives; new exercise price $4.53.
PepGen updates corporate presentation; content not provided in filing excerpt
Company provided an updated corporate presentation dated October 2025.
PepGen Inc. prices $100 million public offering of 31.25 million shares at $3.20 per share
PepGen entered into underwriting agreement with Leerink Partners and Stifel to sell 31,250,000 shares at $3.20 per share.
PepGen reports 53.7% mean splicing correction in DM1 patients at 15 mg/kg dose
Mean splicing correction of 53.7% at 15 mg/kg (n=6) by 22-gene panel at Day 28; all 6 patients responded.
PepGen completes dosing in 15 mg/kg cohort of FREEDOM-DM1; net loss narrows to $23.1M
On track to report topline safety and splicing data from 15 mg/kg cohort in early Q4 2025.
PepGen stockholders elect three Class III directors, ratify KPMG as auditor
Mitchell H. Finer elected with 27,224,040 votes for; 2,082,233 broker non-votes.
PepGen discontinues DMD program after PGN-EDO51 misses dystrophin target; shifts focus to DM1
10 mg/kg PGN-EDO51: total dystrophin only 0.59% of normal (mean increase 0.36%); exon skipping +3.5%.
PepGen Q1 2025 net loss $30.2M; DM1 splicing correction 29.1% at 10 mg/kg
Net loss $30.2M ($0.92/share) in Q1 2025 vs. $18.0M ($0.63/share) in Q1 2024.
PepGen expands board to eight with appointments of Finer and Wyman
Mitchell Finer (PhD), former CSO at bluebird bio, and Lisa Wyman, CTO at Scholar Rock, join board.
PepGen CMO Michelle Mellion resigns, effective April 4, 2025
Michelle L. Mellion, MD, resigned as Chief Medical Officer; departure effective April 4, 2025.
PepGen voluntarily pauses Phase 2 CONNECT2-EDO51 study; awaits 10 mg/kg data from CONNECT1
Temporarily pauses CONNECT2-EDO51 in DMD until review of 10 mg/kg data from ongoing CONNECT1-EDO51 study.
Mean splicing correction of 12.3% (5 mg/kg, n=6) and 29.1% (10 mg/kg, n=4) at 28 days post single dose.
10 mg/kg cohort fully enrolled (n=4); data expected year-end 2025.
PepGen receives FDA clinical hold for Phase 2 DMD trial IND
FDA issued clinical hold for IND to initiate CONNECT2-EDO51 Phase 2 study of PGN-EDO51 in DMD patients.
PepGen Q3 net loss $21.4M; cash $138.9M; DM1/DMD trial updates expected 2025
Net loss of $21.4M ($0.66 per share) vs $23.3M ($0.98) in Q3 2023.
PepGen reports favorable safety profile for PGN-EDO51 in Phase 2 DMD trial at WMS Congress
CONNECT1-EDO51 safety data as of Oct 3: no serious adverse events; all treatment-related AEs mild and resolved.
PepGen board member Christopher Ashton to retire effective Sept 30; board size reduced to 6
Christopher Ashton, PhD, voluntarily resigns from board, effective Sept 30, 2024; also leaves audit and compensation committees.
PepGen appoints Paul Streck, M.D., MBA as EVP, Head of Research & Development
Appoints Paul Streck, M.D., MBA as EVP, Head of R&D effective immediately, joining PepGen Executive Team.
PepGen reports Q2 2024 net loss $28.3M; PGN-EDO51 shows 2.15% exon skipping in CONNECT1
Net loss $28.3M ($0.87/sh) for Q2 2024 vs $19.5M ($0.82/sh) YoY; cash $161.3M, runway into 2026.
PGN-EDO51 5 mg/kg achieved mean exon skipping of 2.15% in biceps tissue at week 13 (n=3).
Afsaneh Mohebbi, Ph.D. appointed SVP, Portfolio & Program Management; previously consultant to PepGen since Jan 2024.
PepGen stockholders approve officer exculpation amendment and elect directors at annual meeting
Stockholders approved Certificate of Amendment to limit liability of certain officers under Delaware law; effective June 20, 2024.
PepGen promotes Michelle Mellion to CMO, Hayley Parker to SVP Global Regulatory Affairs
Michelle Mellion, M.D., promoted to Chief Medical Officer effective immediately.
PepGen Q1 net loss $18.0M, cash $175.2M; key clinical data expected mid-2024
Cash and marketable securities $175.2M as of March 31, 2024, funding operations into 2026.
PepGen amends bylaws to update proxy rules and stockholder meeting procedures
Board adopted Second Amended and Restated By-laws effective March 15, 2024.
PepGen receives FDA orphan drug and rare pediatric disease designations for DMD candidate PGN-EDO51
FDA granted orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapy for DMD.
PepGen reports FY2023 net loss $78.6M; cash runway into 2026 after $80M offering
Enrollment complete for PGN-EDO51 5 mg/kg cohort; preliminary data expected mid-2024.
PepGen gets UK MHRA clearance to start Phase 2 trial of PGN-EDO51 for DMD
MHRA authorized CTA for CONNECT2-EDO51 Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.
PepGen gets FDA Fast Track for PGN-EDODM1 in DM1; Phase 1 data due 2024
FDA granted Fast Track designation for PGN-EDODM1 targeting myotonic dystrophy type 1 (DM1).
PepGen prices $80.1M common stock offering of 7.53M shares at $10.635 per share
Gross proceeds ~$80.1M; net proceeds ~$76.4M after underwriting discounts and expenses.
PepGen appoints Mary Beth DeLena as General Counsel and Secretary
Mary Beth DeLena joins PepGen as General Counsel and Secretary, effective January 17, 2024.
PepGen doses first patient in Phase 2 CONNECT1-EDO51 trial for Duchenne muscular dystrophy
First patient dosed in open-label, multiple ascending dose Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.
PepGen doses first patient in Phase 1 FREEDOM-DM1 trial; data expected in 2024
First patient dosed in Phase 1 FREEDOM-DM1 trial of PGN-EDODM1 for myotonic dystrophy type 1.
PepGen appoints Howard Mayer, M.D. to board of directors
Howard Mayer appointed to PepGen board effective Nov 15, 2023; fills newly created vacancy expanding board to seven members.
PepGen Q3 2023 net loss $23.3M; cash $129.5M; FDA clears FREEDOM-DM1 study in US
Net loss of $23.3M for Q3 2023, vs $18.6M in Q3 2022; R&D expenses $20.5M.
FDA lifts clinical hold on PepGen's DM1 program; US Phase 1 trial to begin
FDA cleared IND for FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in DM1 patients in the US.
PepGen reports preclinical data: PGN-EDODM1 corrects 99% of mis-splicing in DM1 mouse model
EDO platform delivers 25-fold higher oligonucleotide to myotube nuclei vs naked in vitro.
Health Canada issued No Objection Letter for CTA to start FREEDOM-DM1 Phase 1 trial of PGN-EDODM1 in myotonic dystrophy type 1.
PepGen Q2 net loss $19.5M; cash $147M; FDA clinical hold on DM1 trial continues
Net loss of $19.5M for Q2 2023 vs $17.3M YoY; R&D expense $16.9M, G&A $4.2M.
PepGen enters ATM equity offering agreement for up to $100M in common stock
Entered ATM sales agreement with Stifel to sell up to $100M of common stock at market prices.
PepGen stockholders elect Ashton and Resnick as directors, ratify KPMG as auditor
Christopher Ashton elected with 22,342,065 votes for, 78,780 withheld.
PepGen withdraws PGN-EDODM1 Phase 1 timeline guidance pending FDA clinical hold
Withdrawing prior guidance to initiate a Phase 1 study of PGN-EDODM1 in DM1 in H1 2023.
On March 27, 2025, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen” or the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Mitchell Finer, Ph.D. and Lisa Wyman to fill newly created vacancies on the Board resulting from the expansion of the number of members of the Board from six to eight.
On March 27, 2025, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen” or the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Mitchell Finer, Ph.D. and Lisa Wyman to fill newly created vacancies on the Board resulting from the expansion of the number of members of the Board from six to eight.
On March 24, 2025, Michelle L. Mellion, MD resigned from her position as Chief Medical Officer of PepGen Inc.
On September 16, 2024, Christopher Ashton, Ph.D., provided notice of his resignation from the board of directors (the “Board”) of PepGen Inc. (the “Company”), effective as of September 30, 2024.
On November 10, 2023, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen”) on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Howard Mayer to fill a newly created vacancy on the Board resulting from the expansion of the number of members of the Board from six to seven.
Effective September 20, 2022, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen”) on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Habib J. Dable to fill a newly created vacancy on the Board
On July 19, 2022, PepGen Inc. (“PepGen”) was notified that Caroline Godfrey would be transitioning from her role as Senior Vice President of Discovery to member of PepGen’s Scientific Advisory Board, effective August 1, 2022.
Max materiality 0.90 · Median 0.65 · Most common event other_material